PHOSPHODIESTERASE ENZYME INHIBITORS MARKET ANALYSIS

Market News

• Researchers from the John Hopkin University reviewed the trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates and children with primary and secondary pulmonary hypertension (2017).
• Besides, PDE-5 inhibitor sildenafil accidently developed for treating angina, was also found to be effective in erectile dysfunction and now is observed to benefit heart attack patients. Researchers at Karolinska Institutet, Sweden reported in March 2017 that PDE-5 inhibitors prescribed for erectile dysfunction can lower the risk of death of hospitalization for heart failure in men who have had one heart attack in their lifetime.
• Pfizer, Inc. received FDA approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016 for the treatment of mild to moderate atopic dermatitis. Eucrisa is the first non-steroidal topical monotherapy for skin disorder.